
## Frederick L Altice

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6157165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel. Annals of Internal Medicine, 2012, 156, 817.	2.0	519
2	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
3	Public health and international drug policy. Lancet, The, 2016, 387, 1427-1480.	6.3	460
4	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet, The, 2010, 376, 367-387.	6.3	431
5	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet, The, 2019, 394, 1560-1579.	6.3	404
6	Trust and the Acceptance of and Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 47-58.	0.9	343
7	A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug and Alcohol Dependence, 2010, 112, 178-193.	1.6	325
8	Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. Annals of Internal Medicine, 2016, 165, 625.	2.0	322
9	Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic. Journal of Women's Health, 2011, 20, 991-1006.	1.5	280
10	Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases, 2004, 38, 1754-1760.	2.9	229
11	HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S22-S32.	0.9	223
12	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet, The, 2016, 388, 1228-1248.	6.3	213
13	Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1397-1408.	0.4	177
14	Acceptance and Adherence With Antiretroviral Therapy Among HIV-Infected Women in a Correctional Facility. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 341-348.	0.3	167
15	Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science and Medicine, 2002, 55, 235-246.	1.8	167
16	The Era of Adherence to HIV Therapy. Annals of Internal Medicine, 1998, 129, 503.	2.0	164
17	Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet, The, 2016, 388, 1115-1126.	6.3	157
18	The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. Current HIV/AIDS Reports, 2015, 12, 421-436.	1.1	155

#	Article	IF	CITATIONS
19	Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2014, 14, 1189-1195.	4.6	154
20	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	4.6	147
21	Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases, 2007, 45, 770-778.	2.9	140
22	Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases, 2011, 53, 469-479.	2.9	137
23	Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. Aids, 1999, 13, 957-962.	1.0	136
24	Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study. American Journal of Men's Health, 2018, 12, 1843-1854.	0.7	134
25	<p>Adherence to HIV treatment regimens: systematic literature review and meta-analysis</p> . Patient Preference and Adherence, 2019, Volume 13, 475-490.	0.8	125
26	Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. Journal of Drug Issues, 2002, 32, 329-355.	0.6	121
27	Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLoS ONE, 2012, 7, e38335.	1.1	120
28	Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. AIDS and Behavior, 2010, 14, 1213-1226.	1.4	117
29	Correlates of Retention in HIV Care After Release from Jail: Results from a Multi-site Study. AIDS and Behavior, 2013, 17, 156-170.	1.4	113
30	Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal of Drug Policy, 2007, 18, 306-312.	1.6	105
31	Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases, 2004, 38, S376-S387.	2.9	104
32	Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal of Urban Health, 2010, 87, 592-602.	1.8	103
33	Optimization of Human Immunodeficiency Virus Treatment During Incarceration. JAMA Internal Medicine, 2014, 174, 721.	2.6	100
34	Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS and Behavior, 2011, 15, 1635-1646.	1.4	97
35	Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 563-572.	0.9	96
36	Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. International Journal of Drug Policy, 2015, 26, 922-935.	1.6	95

#	Article	IF	CITATIONS
37	Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Current HIV/AIDS Reports, 2016, 13, 241-255.	1.1	94
38	Optimizing Care for HIV-Infected People Who Use Drugs: Evidence-Based Approaches to Overcoming Healthcare Disparities. Clinical Infectious Diseases, 2013, 57, 1309-1317.	2.9	90
39	A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs. Current HIV/AIDS Reports, 2012, 9, 287-312.	1.1	89
40	Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. Aids, 2011, 25, 279-290.	1.0	86
41	Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet, The, 2016, 388, 1103-1114.	6.3	86
42	Effect of Ebola Progression on Transmission and Control in Liberia. Annals of Internal Medicine, 2015, 162, 11-17.	2.0	83
43	Adherence to HIV Treatment and Care Among Previously Homeless Jail Detainees. AIDS and Behavior, 2013, 17, 2654-2666.	1.4	78
44	Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic. Journal of Community Health, 2014, 39, 922-934.	1.9	78
45	HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal of Drug Policy, 2007, 18, 326-328.	1.6	76
46	Clinical Care of the HIV-Infected Drug User. Infectious Disease Clinics of North America, 2007, 21, 149-179.	1.9	74
47	Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug and Alcohol Dependence, 2014, 134, 106-114.	1.6	74
48	Challenges in managing HIV in people who use drugs. Current Opinion in Infectious Diseases, 2015, 28, 10-16.	1.3	74
49	Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infectious Diseases, The, 2018, 18, 215-224.	4.6	74
50	Predictors of HIV Infection Among Newly Sentenced Male Prisoners. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 444-453.	0.3	72
51	Pilot Study to Enhance HIV Care Using Needle Exchange-Based Health Services for Out-of-Treatment Injecting Drug Users. Journal of Urban Health, 2003, 80, 416-427.	1.8	72
52	Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 43-53.	0.9	72
53	Gender Disparities in HIV Treatment Outcomes Following Release From Jail: Results From a Multicenter Study. American Journal of Public Health, 2014, 104, 434-441.	1.5	71
54	An Information–Motivation–Behavioral Skills Model of PrEP Uptake. AIDS and Behavior, 2018, 22, 3603-3616.	1.4	70

#	Article	IF	CITATIONS
55	The opioid crisis and HIV in the USA: deadly synergies. Lancet, The, 2021, 397, 1139-1150.	6.3	68
56	Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug and Alcohol Dependence, 2013, 131, 127-135.	1.6	66
57	Adherence to Hepatitis B Virus Vaccination At Syringe Exchange Sites. Journal of Urban Health, 2005, 82, 151-161.	1.8	65
58	Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports, 2005, 2, 165-170.	1.1	65
59	Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 366-377.	0.6	64
60	Validation of a Brief Measure of Opioid Dependence. Journal of Correctional Health Care, 2015, 21, 12-26.	0.2	64
61	Correlates of HIV Infection Among Incarcerated Women: Implications for Improving Detection of HIV Infection. Journal of Urban Health, 2005, 82, 312-326.	1.8	63
62	Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S68-S75.	0.9	63
63	Burden of Infectious Diseases, Substance Use Disorders, and Mental Illness among Ukrainian Prisoners Transitioning to the Community. PLoS ONE, 2013, 8, e59643.	1.1	63
64	Creating, reinforcing, and resisting the gender binary: a qualitative study of transgender women's healthcare experiences in sex-segregated jails and prisons. International Journal of Prisoner Health, 2018, 14, 69-88.	0.5	63
65	"Bureaucracy & Beliefsâ€: Assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs: Education, Prevention and Policy, 2015, 22, 255-262.	0.8	62
66	Social Network Strategies to Address HIV Prevention and Treatment Continuum of Care Among At-risk and HIV-infected Substance Users: A Systematic Scoping Review. AIDS and Behavior, 2017, 21, 1183-1207.	1.4	62
67	Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug and Alcohol Dependence, 2013, 132, 378-382.	1.6	61
68	Understanding the Revolving Door: Individual and Structural-Level Predictors of Recidivism Among Individuals with HIV Leaving Jail. AIDS and Behavior, 2013, 17, 145-155.	1.4	61
69	Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. American Journal of Drug and Alcohol Abuse, 2009, 35, 68-72.	1.1	60
70	Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S39-S45.	0.9	60
71	Patterns of Homelessness and Implications for HIV Health After Release from Jail. AIDS and Behavior, 2013, 17, 181-194.	1.4	60
72	An assessment of health-care students' attitudes toward patients with or at high risk for HIV: implications for education and cultural competency. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1223-1228.	0.6	60

#	Article	IF	CITATIONS
73	Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola Outbreak Reveals Clustered Transmission. Clinical Infectious Diseases, 2015, 60, 1079-1082.	2.9	59
74	Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal of Substance Abuse Treatment, 2012, 43, 451-457.	1.5	58
75	The Diagnostic Performance of a Single GeneXpert MTB/RIF Assay in an Intensified Tuberculosis Case Finding Survey among HIV-Infected Prisoners in Malaysia. PLoS ONE, 2013, 8, e73717.	1.1	58
76	Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug and Alcohol Dependence, 2017, 173, 107-116.	1.6	57
77	Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study. The Lancet Global Health, 2017, 5, e198-e207.	2.9	57
78	Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Preference and Adherence, 2016, 10, 683.	0.8	56
79	The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment. Journal of Substance Abuse Treatment, 2016, 66, 37-47.	1.5	56
80	Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study. Lancet HIV,the, 2018, 5, e96-e106.	2.1	55
81	The impact of needle exchange-based health services on emergency department use. Journal of General Internal Medicine, 2002, 17, 341-348.	1.3	54
82	Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases, 2008, 47, 952-961.	2.9	54
83	HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. Lancet HIV,the, 2014, 1, e77-e84.	2.1	54
84	Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 545-553.	0.6	54
85	Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, S48-S53.	0.9	53
86	Trust and other Characteristics Associated with Health Care Utilization by Injection Drug Users. Journal of Drug Issues, 2006, 36, 953-974.	0.6	53
87	Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting. Clinical Infectious Diseases, 2006, 42, 716-721.	2.9	53
88	Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS and Behavior, 2013, 17, 118-127.	1.4	52
89	Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. AIDS and Behavior, 2017, 21, 1299-1308.	1.4	52
90	Testing for HIV, Sexually Transmitted Infections, and Viral Hepatitis in Jails: Still a Missed Opportunity for Public Health and HIV Prevention. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S78-S83.	0.9	51

#	Article	IF	CITATIONS
91	Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 93-104.	0.6	51
92	Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?. Current HIV/AIDS Reports, 2018, 15, 266-275.	1.1	50
93	Implementing methadone maintenance treatment in prisons in Malaysia. Bulletin of the World Health Organization, 2013, 91, 124-129.	1.5	49
94	Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, S155-S161.	0.9	49
95	Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers. Journal of Urban Health, 2015, 92, 193-213.	1.8	49
96	The management of methamphetamine use in sexual settings among men who have sex with men in Malaysia. International Journal of Drug Policy, 2018, 55, 256-262.	1.6	49
97	Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 92-100.	0.9	49
98	A Prospective Controlled Trial of Routine Opt-Out HIV Testing in a Men's Jail. PLoS ONE, 2009, 4, e8056.	1.1	48
99	Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug and Alcohol Dependence, 2015, 148, 47-55.	1.6	48
100	Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Clinical Trials, 2007, 8, 205-212.	2.0	47
101	Latent class analysis of substance use among men who have sex with men in Malaysia: Findings from the Asian Internet MSM Sex Survey. Drug and Alcohol Dependence, 2015, 151, 31-37.	1.6	47
102	Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. Journal of Community Health, 1998, 23, 419-440.	1.9	46
103	Prevention of HIV Infection in Street-Recruited Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 63-70.	0.9	46
104	Effectiveness of a Mobile Medical Van in Providing Screening Services for STDs and HIV. Public Health Nursing, 2002, 19, 345-353.	0.7	46
105	HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. American Journal of Drug and Alcohol Abuse, 2011, 37, 12-21.	1.1	45
106	Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S83-S90.	0.9	45
107	Exploring intentions to discriminate against patients living with <scp>HIV</scp> / <scp>AIDS</scp> among future healthcare providers in <scp>M</scp> alaysia. Tropical Medicine and International Health, 2014, 19, 672-679.	1.0	45
108	Screening for Drug and Alcohol Use Disorders and Their Association with HIV-Related Sexual Risk Behaviors among Men Who Have Sex with Men in Peru. PLoS ONE, 2013, 8, e69966.	1.1	45

#	Article	IF	CITATIONS
109	High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study. International Journal of Drug Policy, 2015, 26, 675-681.	1.6	43
110	Communication technology use and mHealth acceptance among HIV-infected men who have sex with men in Peru: implications for HIV prevention and treatment. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 273-282.	0.6	43
111	Routine Opt-Out HIV Testing Strategies in a Female Jail Setting: A Prospective Controlled Trial. PLoS ONE, 2009, 4, e7648.	1.1	43
112	The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases, 2006, 43, S178-S183.	2.9	42
113	Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug and Alcohol Dependence, 2016, 165, 213-220.	1.6	42
114	Stigma Toward Men Who Have Sex with Men Among Future Healthcare Providers in Malaysia: Would More Interpersonal Contact Reduce Prejudice?. AIDS and Behavior, 2016, 20, 98-106.	1.4	42
115	Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. Aids, 2006, 20, 783-784.	1.0	41
116	Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. American Journal of Drug and Alcohol Abuse, 2012, 38, 206-212.	1.1	41
117	Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment. International Journal of Drug Policy, 2016, 37, 9-20.	1.6	41
118	A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review of Clinical Pharmacology, 2013, 6, 249-269.	1.3	40
119	Linkage and retention in <scp>HCV</scp> care for <scp>HIV</scp> â€infected populations: early data from the <scp>DAA</scp> era. Journal of the International AIDS Society, 2018, 21, e25051.	1.2	40
120	Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 176-181.	0.9	39
121	Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: Implications for secondary prevention. Drug and Alcohol Dependence, 2011, 116, 151-157.	1.6	39
122	Accessibility and utilization patterns of a mobile medical clinic among vulnerable populations. Health and Place, 2014, 28, 153-166.	1.5	39
123	Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal of Substance Abuse Treatment, 2019, 100, 18-28.	1.5	39
124	The impact of needle exchange-based health services on emergency department use. Journal of General Internal Medicine, 2002, 17, 341-8.	1.3	39
125	Psychiatric and Substance Abuse Comorbidity among HIV Seropositive and HIV Seronegative Prisoners in Malaysia. American Journal of Drug and Alcohol Abuse, 2010, 36, 31-38.	1.1	38
126	Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS and Behavior, 2013, 17, 171-180.	1.4	38

#	Article	IF	CITATIONS
127	Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health, 2014, 14, 22.	1.2	38
128	Under-reporting and case fatality estimates for emerging epidemics. BMJ, The, 2015, 350, h1115-h1115.	3.0	38
129	Within-prison drug injection among HIV-infected male prisoners in Indonesia: A highly constrained choice. Drug and Alcohol Dependence, 2015, 149, 71-79.	1.6	38
130	Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 976-983.	0.6	37
131	Early Identification of HIV: Empirical Support for Jail-Based Screening. PLoS ONE, 2012, 7, e37603.	1.1	37
132	At the crossroads: <scp>HIV</scp> prevention and treatment for people who inject drugs in <scp>U</scp> kraine. Addiction, 2013, 108, 1697-1699.	1.7	37
133	Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators. AIDS and Behavior, 2016, 20, 2950-2960.	1.4	37
134	Use of Smartphone to Seek Sexual Health Information Online Among Malaysian Men Who Have Sex with Men (MSM): Implications for mHealth Intervention to Increase HIV Testing and Reduce HIV Risks. Journal of Community Health, 2020, 45, 10-19.	1.9	37
135	Absence of Antiretroviral Therapy and Other Risk Factors for Morbidity and Mortality in Malaysian Compulsory Drug Detention and Rehabilitation Centers. PLoS ONE, 2012, 7, e44249.	1.1	37
136	HIV control efforts should directly address incarceration. Lancet Infectious Diseases, The, 2007, 7, 568-569.	4.6	36
137	Within-prison drug injection among HIV-infected Ukrainian prisoners: Prevalence and correlates of an extremely high-risk behaviour. International Journal of Drug Policy, 2014, 25, 845-852.	1.6	36
138	In their own voices: Breaking the vicious cycle of addiction, treatment and criminal justice among people who inject drugs in Ukraine. Drugs: Education, Prevention and Policy, 2016, 23, 163-175.	0.8	36
139	Improving correctional healthcare providers' ability to care for transgender patients: Development and evaluation of a theory-driven cultural and clinical competence intervention. Social Science and Medicine, 2017, 195, 159-169.	1.8	36
140	Staying hepatitis C negative: A systematic review and metaâ€analysis of cure and reinfection in people who inject drugs. Liver International, 2019, 39, 2244-2260.	1.9	36
141	Prevention of HIV Infection in Street-Recruited Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 63-70.	0.9	35
142	Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. Journal of Drug Issues, 2004, 34, 451-480.	0.6	35
143	High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes. Drug and Alcohol Dependence, 2013, 133, 154-160.	1.6	35
144	Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. AIDS and Behavior, 2014, 18, 120-127.	1.4	35

#	Article	IF	CITATIONS
145	Gender identity, healthcare access, and risk reduction among Malaysia's <i>mak nyah</i> community. Global Public Health, 2016, 11, 1010-1025.	1.0	35
146	Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 288-295.	0.9	35
147	The Influence of Housing Status on the HIV Continuum of Care: Results From a Multisite Study of Patient Navigation Models to Build a Medical Home for People Living With HIV Experiencing Homelessness. American Journal of Public Health, 2018, 108, S539-S545.	1.5	35
148	Pharmacological pain control for human immunodeficiency virus–infected adults with a history of drug dependence. Journal of Substance Abuse Treatment, 2007, 32, 399-409.	1.5	34
149	Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. International Journal of Drug Policy, 2013, 24, e91-e98.	1.6	34
150	Gender Differences in Baseline Health, Needs at Release, and Predictors of Care Engagement Among HIV-Positive Clients Leaving Jail. AIDS and Behavior, 2013, 17, 195-202.	1.4	34
151	High rates of unprotected anal intercourse with regular and casual partners and associated risk factors in a sample of ethnic Malay men who have sex with men (MSM) in Penang, Malaysia. Sexually Transmitted Infections, 2013, 89, 642-649.	0.8	34
152	The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLoS ONE, 2013, 8, e64321.	1.1	34
153	Emergency Department Use by Released Prisoners with HIV: An Observational Longitudinal Study. PLoS ONE, 2012, 7, e42416.	1.1	34
154	Behavioral Counseling Content for Optimizing the Use of Buprenorphine for Treatment of Opioid Dependence in Community-Based Settings: A Review of the Empirical Evidence. American Journal of Drug and Alcohol Abuse, 2007, 33, 643-654.	1.1	33
155	Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS and Behavior, 2008, 12, 284-293.	1.4	33
156	Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy. Journal of the International AIDS Society, 2016, 19, 20897.	1.2	33
157	Retention in HIV care during the 3 years following release from incarceration: A cohort study. PLoS Medicine, 2018, 15, e1002667.	3.9	33
158	Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. American Journal of Drug and Alcohol Abuse, 2011, 37, 1-11.	1.1	32
159	Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1538-1544.	0.6	32
160	Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials, 2014, 39, 256-268.	0.8	32
161	Harnessing Case Isolation and Ring Vaccination to Control Ebola. PLoS Neglected Tropical Diseases, 2015, 9, e0003794.	1.3	31
162	Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. AIDS and Behavior, 2017, 21, 3100-3110.	1.4	31

#	Article	IF	CITATIONS
163	A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Health-Related Quality of Life among Incarcerated Malaysian Men with HIV and Opioid Dependence. AIDS and Behavior, 2017, 21, 1059-1069.	1.4	31
164	Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS and Behavior, 2018, 22, 1228-1238.	1.4	31
165	The realâ€world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction, 2021, 116, 83-93.	1.7	31
166	Interventions to Mitigate COVID-19 Misinformation: A Systematic Review and Meta-Analysis. Journal of Health Communication, 2021, 26, 846-857.	1.2	31
167	Adaptation of an Evidence-Based Intervention Targeting HIV-Infected Prisoners Transitioning to the Community: The Process and Outcome of Formative Research for the Positive Living Using Safety (PLUS) Intervention. AIDS Patient Care and STDs, 2009, 23, 277-287.	1.1	30
168	A review of medical and substance use co-morbidities in Central Asian prisons: Implications for HIV prevention and treatment. Drug and Alcohol Dependence, 2013, 132, S25-S31.	1.6	30
169	Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug and Alcohol Dependence, 2015, 151, 68-75.	1.6	30
170	Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal of Substance Abuse Treatment, 2021, 121, 108164.	1.5	30
171	HIV-Related Research in Correctional Populations: Now is the Time. Current HIV/AIDS Reports, 2011, 8, 288-296.	1.1	29
172	Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug and Alcohol Dependence, 2015, 157, 158-165.	1.6	29
173	Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS and Behavior, 2018, 22, 2640-2649.	1.4	29
174	Factors Associated with Medical Doctors' Intentions to Discriminate Against Transgender Patients in Kuala Lumpur, Malaysia. LGBT Health, 2018, 5, 61-68.	1.8	29
175	HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy. Current Psychiatry Reports, 2019, 21, 47.	2.1	29
176	An exploratory qualitative assessment of self-reported treatment outcomes and satisfaction among patients accessing an innovative voluntary drug treatment centre in Malaysia. International Journal of Drug Policy, 2015, 26, 175-182.	1.6	28
177	Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug and Alcohol Dependence, 2017, 174, 158-170.	1.6	28
178	Prevalence of Human Immunodeficiency Virus and Sexually Transmitted Infections Among Cisgender and Transgender Women Sex Workers in Greater Kuala Lumpur, Malaysia: Results From a Respondent-Driven Sampling Study. Sexually Transmitted Diseases, 2017, 44, 663-670.	0.8	28
179	Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials, 2012, 33, 436-444.	0.8	27
180	Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, and Policy, 2017, 12, 24.	1.0	27

#	Article	IF	CITATIONS
181	Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. Journal of Adolescent Health, 2018, 62, S18-S26.	1.2	27
182	Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. American Journal of Drug and Alcohol Abuse, 2008, 34, 511-517.	1.1	26
183	Undiagnosed pulmonary tuberculosis among prisoners in Malaysia: an overlooked risk for tuberculosis in the community. Tropical Medicine and International Health, 2016, 21, 1049-1058.	1.0	26
184	Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. Lancet HIV,the, 2020, 7, e121-e128.	2.1	26
185	Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. American Journal of Drug and Alcohol Abuse, 2007, 33, 869-874.	1.1	25
186	An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal of Substance Abuse Treatment, 2014, 47, 35-40.	1.5	25
187	Sex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates. American Journal of Public Health, 2015, 105, 1901-1910.	1.5	25
188	The syndemic of HIV, HIV-related risk and multiple co-morbidities among women who use drugs in Malaysia: Important targets for intervention. Addictive Behaviors, 2016, 53, 31-39.	1.7	25
189	Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine. International Journal of Drug Policy, 2017, 49, 48-53.	1.6	25
190	Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Frontiers in Immunology, 2017, 8, 561.	2.2	25
191	Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. Epidemiologic Reviews, 2020, 42, 41-56.	1.3	25
192	Hepatitis B Virus Infection in US Correctional Facilities: A Review of Diagnosis, Management, and Public Health Implications. Journal of Urban Health, 2009, 86, 263-279.	1.8	24
193	Patterns of substance use and correlates of lifetime and active injection drug use among women in Malaysia. American Journal of Drug and Alcohol Abuse, 2016, 42, 98-110.	1.1	24
194	Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine. Drug and Alcohol Dependence, 2017, 173, 132-138.	1.6	24
195	Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal of Drug Policy, 2017, 47, 187-195.	1.6	24
196	Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments. International Journal of Prisoner Health, 2018, 14, 175-187.	0.5	24
197	Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal of Substance Abuse Treatment, 2020, 117, 108058.	1.5	24
198	Cost-Effectiveness of HIV Screening for Incarcerated Pregnant Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 163-173.	0.9	23

#	Article	IF	CITATIONS
199	Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S62-S67.	0.9	23
200	Partner violence and health among HIV-infected jail detainees. International Journal of Prisoner Health, 2013, 9, 124-141.	0.5	23
201	Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users. Substance Use and Misuse, 2014, 49, 1017-1024.	0.7	23
202	Correlates and Experiences of HIV Stigma in Prisoners Living With HIV in Indonesia: A Mixed-Method Analysis. Journal of the Association of Nurses in AIDS Care, 2015, 26, 743-757.	0.4	23
203	Physician Decisions to Defer Antiretroviral Therapy in Key Populations: Implications for Reducing Human Immunodeficiency Virus Incidence and Mortality in Malaysia. Open Forum Infectious Diseases, 2017, 4, ofw219.	0.4	23
204	Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal of Drug Policy, 2022, 101, 103570.	1.6	23
205	Women Living with Drug Abuse and HIV Disease: Drug Abuse Treatment Access and Secondary Prevention Issues. Journal of Psychoactive Drugs, 1995, 27, 401-411.	1.0	22
206	Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug and Alcohol Dependence, 2009, 105, 234-239.	1.6	22
207	Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials, 2014, 37, 209-218.	0.8	22
208	Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health and Justice, 2015, 3, 18.	0.9	22
209	Accessing methadone within Moldovan prisons: Prejudice and myths amplified by peers. International Journal of Drug Policy, 2016, 29, 91-95.	1.6	22
210	HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 22-31.	0.6	22
211	All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007–14: a retrospective observational cohort study. Lancet HIV,the, 2018, 5, e617-e628.	2.1	22
212	Testing an Optimized Community-Based Human Immunodeficiency Virus (HIV) Risk Reduction and Antiretroviral Adherence Intervention for HIV-Infected Injection Drug Users. Substance Abuse, 2011, 32, 16-26.	1.1	21
213	Sexual Risk Behaviors Among Adolescents in Port-au-Prince, Haiti. AIDS and Behavior, 2014, 18, 1595-1603.	1.4	21
214	Preâ€incarceration police harassment, drug addiction and HIV risk behaviours among prisoners in Kyrgyzstan and Azerbaijan: results from a nationally representative crossâ€sectional study. Journal of the International AIDS Society, 2016, 19, 20880.	1.2	21
215	Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia. Journal of NeuroImmune Pharmacology, 2016, 11, 446-455.	2.1	21
216	The Influence of Medication Attitudes on Utilization of Antiretroviral Therapy (ART) in Indonesian Prisons. AIDS and Behavior, 2016, 20, 1026-1038.	1.4	21

#	Article	IF	CITATIONS
217	"You Have to Keep Yourself Hidden― Perspectives From Malaysian Malay-Muslim Men Who Have Sex With Men on Policy, Network, Community, and Individual Influences on HIV Risk. Journal of Homosexuality, 2020, 67, 104-126.	1.3	21
218	HIV testing in correctional institutions: evaluating existing strategies, setting new standards. AIDS & Public Policy Journal, 2005, 20, 3-24.	0.2	21
219	Extending a lifeline to people with HIV and opioid use disorder during the war in Ukraine. Lancet Public Health, The, 2022, 7, e482-e484.	4.7	21
220	COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines, 2022, 10, 424.	2.1	21
221	Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. Contemporary Clinical Trials, 2017, 59, 1-12.	0.8	20
222	Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal of Drug Policy, 2017, 48, 44-53.	1.6	20
223	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. Lancet Psychiatry,the, 2021, 8, 301-309.	3.7	20
224	NEXT STEPS FOR UKRAINE ABOLITION OF HIV REGISTRIES, IMPLEMENTATION OF ROUTINE HUMAN IMMUNODEFICIENCY VIRUS TESTING AND EXPANSION OF SERVICES. Addiction, 2010, 105, 569-570.	1.7	19
225	Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. International Journal of Prisoner Health, 2016, 12, 253-269.	0.5	19
226	The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. AIDS and Behavior, 2017, 21, 1070-1081.	1.4	19
227	A systematic review of alcohol use and sexual risk-taking in Latin America. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2013, 34, 267-74.	0.6	19
228	Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia. Journal of Substance Abuse Treatment, 2015, 54, 29-36.	1.5	18
229	Prevalence and correlates of latent tuberculosis infection among employees of a high security prison in Malaysia. Occupational and Environmental Medicine, 2015, 72, 442-447.	1.3	18
230	HIV Prevalence Among People Who Inject Drugs in Greater Kuala Lumpur Recruited Using Respondent-Driven Sampling. AIDS and Behavior, 2015, 19, 2347-2357.	1.4	18
231	Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia. Drug and Alcohol Dependence, 2016, 164, 120-127.	1.6	18
232	Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders. American Journal of Men's Health, 2017, 11, 1269-1278.	0.7	18
233	Strategies to Implement Pre-exposure Prophylaxis with Men Who Have Sex with Men in Ukraine. AIDS and Behavior, 2018, 22, 1100-1112.	1.4	18
234	Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. Lancet HIV,the, 2022, 9, e42-e53.	2.1	18

#	Article	IF	CITATIONS
235	Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 511-514.	0.9	17
236	Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLoS ONE, 2012, 7, e31786.	1.1	17
237	Latent Tuberculosis Infection Screening in Foreign-Born Populations: A Successful Mobile Clinic Outreach Model. American Journal of Public Health, 2014, 104, 1508-1515.	1.5	17
238	A Call to Action: A Blueprint for Academic Health Sciences in the Era of Mass Incarceration. Journal of Health Care for the Poor and Underserved, 2016, 27, 5-17.	0.4	17
239	Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal of Substance Abuse Treatment, 2018, 87, 1-8.	1.5	17
240	Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug and Alcohol Dependence, 2018, 190, 82-88.	1.6	17
241	Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLoS ONE, 2016, 11, e0147821.	1.1	17
242	Safer Injection Sites in New York City: A Utilization Survey of Injection Drug Users. Journal of Drug Issues, 2003, 33, 733-750.	0.6	16
243	Strategies for Primary HIV Prevention That Target Behavioral Change. Clinical Infectious Diseases, 2007, 45, S300-S307.	2.9	16
244	The Association Between History of Violence and HIV Risk. Women's Health Issues, 2007, 17, 210-216.	0.9	16
245	Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission. Addiction, 2015, 110, 1869-1871.	1.7	16
246	Emergency Department Use among HIV-Infected Released Jail Detainees. Journal of Urban Health, 2015, 92, 108-135.	1.8	16
247	An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. Journal of Substance Abuse Treatment, 2016, 63, 61-65.	1.5	16
248	Why People Who Inject Drugs Voluntarily Transition Off Methadone in Ukraine. Qualitative Health Research, 2017, 27, 2057-2070.	1.0	16
249	Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug and Alcohol Dependence, 2017, 179, 213-219.	1.6	16
250	Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. International Journal of Drug Policy, 2018, 57, 11-17.	1.6	16
251	Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. International Journal of Environmental Research and Public Health, 2019, 16, 1592.	1.2	16
252	HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 166-173.	0.9	16

#	Article	IF	CITATIONS
253	Evaluating Physicians' Intention to Discriminate Against Patients Living with HIV in Malaysia. AIDS and Behavior, 2019, 23, 1039-1047.	1.4	16
254	Identifying and managing infectious disease syndemics in patients with HIV. Current Opinion in HIV and AIDS, 2020, 15, 232-242.	1.5	16
255	Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 555-563.	0.9	15
256	Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review of Clinical Pharmacology, 2008, 1, 115-127.	1.3	15
257	Medication Persistence of HIV-infected Drug Users on Directly Administered Antiretroviral Therapy. AIDS and Behavior, 2013, 17, 113-121.	1.4	15
258	Frequent Emergency Department Use Among Released Prisoners With Human Immunodeficiency Virus: Characterization Including a Novel Multimorbidity Index. Academic Emergency Medicine, 2013, 20, 79-88.	0.8	15
259	Ukrainian prisoners and community reentry challenges: implications for transitional care. International Journal of Prisoner Health, 2013, 9, 5-19.	0.5	15
260	Tuberculosis screening in a novel substance abuse treatment center in Malaysia: Implications for a comprehensive approach for integrated care. Journal of Substance Abuse Treatment, 2014, 46, 144-149.	1.5	15
261	Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases, 2017, 4, ofx092.	0.4	15
262	A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal of Substance Abuse Treatment, 2018, 86, 86-93.	1.5	15
263	Costâ€effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction, 2020, 115, 437-450.	1.7	15
264	Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: results from a conjoint-based analysis. BMC Public Health, 2020, 20, 1777.	1.2	15
265	Response to the COVID-19 Outbreak in Urban Settings in China. Journal of Urban Health, 2021, 98, 41-52.	1.8	15
266	COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit. BMC Public Health, 2022, 22, 446.	1.2	15
267	Adapting an Evidence-Based Intervention Targeting HIV-Infected Prisoners in Malaysia. AIDS Research and Treatment, 2011, 2011, 1-14.	0.3	14
268	Latent Tuberculosis Infection: Screening and Treatment in an Urban Setting. Journal of Community Health, 2013, 38, 941-950.	1.9	14
269	Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. International Journal of Drug Policy, 2017, 45, 56-63.	1.6	14
270	Comparison of Tuberculin Skin Testing Reactivity in Opioid-Dependent Patients Seeking Treatment with Methadone versus Buprenorphine: Policy Implications for Tuberculosis Screening. American Journal of Drug and Alcohol Abuse, 2009, 35, 439-444.	1.1	13

#	Article	IF	CITATIONS
271	Correlates of HIV infection and being unaware of HIV status among soonâ€ŧoâ€beâ€released Ukrainian prisoners. Journal of the International AIDS Society, 2014, 17, 19005.	1.2	13
272	Pretreatment Drug use Characteristics and Experiences among Patients in a Voluntary Substance Abuse Treatment Center in Malaysia: A Mixed-Methods Approach. Substance Abuse, 2016, 37, 542-549.	1.1	13
273	Leveraging the U.S. Criminal Justice System to Access Women for HIV Interventions. AIDS and Behavior, 2017, 21, 3527-3548.	1.4	13
274	Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Substance Use and Misuse, 2018, 53, 1519-1528.	0.7	13
275	Willingness to Use HIV Self-Testing and Associated Factors Among Transgender Women in Malaysia. Transgender Health, 2020, 5, 182-190.	1.2	13
276	Mobile Health Technology Use and the Acceptability of an mHealth Platform for HIV Prevention Among Men Who Have Sex With Men in Malaysia: Cross-sectional Respondent-Driven Sampling Survey. Journal of Medical Internet Research, 2022, 24, e36917.	2.1	13
277	Randomized, Controlled Trials of Directly Administered Antiretroviral Therapy for HIV-Infected Patients: Questions about Study Population and Analytical Approach. Clinical Infectious Diseases, 2006, 43, 1221-1222.	2.9	12
278	Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 462-474.	0.6	12
279	A Qualitative Assessment of Alcohol Consumption and Sexual Risk Behaviors Among Men Who Have Sex With Men and Transgender Women in Peru. Substance Use and Misuse, 2017, 52, 831-839.	0.7	12
280	Assessment of an Innovative Voluntary Substance Abuse Treatment Program Designed to Replace Compulsory Drug Detention Centers in Malaysia. Substance Use and Misuse, 2018, 53, 249-259.	0.7	12
281	Factors Associated with HIV Viral Suppression Among Transgender Women in Lima, Peru. LGBT Health, 2018, 5, 477-483.	1.8	12
282	<p>Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis</p> . Patient Preference and Adherence, 2020, Volume 14, 107-118.	0.8	12
283	A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health and Justice, 2014, 2, .	0.9	11
284	Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain―Harmonization Consortium. AIDS and Behavior, 2017, 21, 2945-2957.	1.4	11
285	Innovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting. Journal of Health Care for the Poor and Underserved, 2017, 28, 643-662.	0.4	11
286	Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug and Alcohol Dependence, 2019, 194, 59-68.	1.6	11
287	Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. Drug and Alcohol Dependence, 2021, 219, 108477.	1.6	11
288	â€~Krokodil' and what a long strange trip it's been. International Journal of Drug Policy, 2013, 24, 279-280.	1.6	10

#	Article	IF	CITATIONS
289	The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLoS ONE, 2015, 10, e0123482.	1.1	10
290	Retrospective Analysis of the 2014–2015 Ebola Epidemic in Liberia. American Journal of Tropical Medicine and Hygiene, 2016, 94, 833-839.	0.6	10
291	A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan. Harm Reduction Journal, 2017, 14, 43.	1.3	10
292	Predictors of mortality within prison and after release among persons living with HIV in Indonesia. Research and Reports in Tropical Medicine, 2017, Volume 8, 25-35.	2.8	10
293	Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine. Journal of Urban Health, 2018, 95, 508-522.	1.8	10
294	Clinical Guidelines and Pharmacist Intervention Program for HIV-Infected Patients Requiring Granulocyte Colony-Stimulating Factor Therapy. Pharmacotherapy, 1999, 19, 356-362.	1.2	9
295	A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description. Contemporary Clinical Trials, 2015, 44, 95-102.	0.8	9
296	Trials and tribulations of conducting bio-behavioral surveys in prisons: implementation science and lessons from Ukraine. International Journal of Prisoner Health, 2016, 12, 78-87.	0.5	9
297	Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. International Journal of Drug Policy, 2017, 47, 144-152.	1.6	9
298	HIV Testing and awareness of HIV status among people who inject drugs in greater Kuala Lumpur, Malaysia AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 59-64.	0.6	9
299	Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 283-287.	0.9	9
300	Correlates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1341-1350.	0.6	9
301	Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling. International Journal of Drug Policy, 2019, 67, 91-101.	1.6	9
302	Assessing mobile health feasibility and acceptability among HIV-infected cocaine users and their healthcare providers: guidance for implementing an intervention. MHealth, 2020, 6, 4-4.	0.9	9
303	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. International Journal of Population Data Science, 2020, 5, 1145.	0.1	9
304	Editorial comment: why treat three conditions when it is one patient?. Aids Reader, 2003, 13, 378-9.	0.3	9
305	Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases, 2006, 43, S169-S172.	2.9	8
306	Correlates of Recent HIV Testing Among Transgender Women in Greater Kuala Lumpur, Malaysia. LGBT Health, 2018, 5, 484-493.	1.8	8

#	Article	IF	CITATIONS
307	HIV Sero-Status Non-disclosure Among HIV-Infected Opioid-Dependent Individuals: The Roles of HIV-Related Stigma, Risk Behavior, and Social Support. Journal of Community Health, 2019, 44, 112-120.	1.9	8
308	The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal of Viral Hepatitis, 2019, 26, 329-336.	1.0	8
309	Adherence to Antiretroviral Therapy Among Incarcerated Persons with HIV: Associations with Methadone and Perceived Safety. AIDS and Behavior, 2019, 23, 2048-2058.	1.4	8
310	A qualitative study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction. Harm Reduction Journal, 2020, 17, 86.	1.3	8
311	Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases, 2021, 72, 755-763.	2.9	8
312	Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People Who Inject Drugs. Substance Use and Misuse, 2021, 56, 979-987.	0.7	8
313	Decisional considerations for methadone uptake in Kyrgyz prisons: The importance of understanding context and providing accurate information. International Journal of Drug Policy, 2021, 94, 103209.	1.6	8
314	Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. Patient Preference and Adherence, 2021, Volume 15, 1913-1927.	0.8	8
315	Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health Model. , 2007, , 535-555.		8
316	Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. Aids, 2020, 34, 2285-2294.	1.0	8
317	Relying on Injection Drug Users to Access and Adhere to HIV Therapeutics. Journal of Drug Issues, 2012, 42, 127-146.	0.6	7
318	Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal of Correctional Health Care, 2015, 21, 125-139.	0.2	7
319	Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia. HIV Research and Clinical Practice, 2019, 20, 12-23.	1.1	7
320	Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLoS ONE, 2015, 10, e0116694.	1.1	7
321	<i>Letter to the Editor:</i> Observations on Implementing Routine HIV Testing in Jails. AIDS Patient Care and STDs, 2007, 21, 715-716.	1.1	6
322	DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. Archives of Internal Medicine, 2010, 170, 109.	4.3	6
323	Correlates of Having Never Been HIV Tested among Entrants to Substance Abuse Treatment Clinics: Empiric Findings from Real-World New England Settings. Journal of Psychoactive Drugs, 2014, 46, 208-214.	1.0	6
324	Explaining poor health-seeking among HIV-infected released prisoners. International Journal of Prisoner Health, 2015, 11, 209-224.	0.5	6

#	Article	IF	CITATIONS
325	The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling. International Journal of Drug Policy, 2016, 37, 98-106.	1.6	6
326	Pre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis. AIDS and Behavior, 2019, 23, 534-543.	1.4	6
327	Prisons. Current Opinion in HIV and AIDS, 2019, 14, 415-422.	1.5	6
328	Assessing mobile technology use and mHealth acceptance among HIV-positive men who have sex with men and transgender women in Malaysia. PLoS ONE, 2021, 16, e0248705.	1.1	6
329	"Who are You and What are You Doing Here?†Social Capital and Barriers to Movement along the HIV Care Cascade among Tajikistani Migrants with HIV to Russia. AIDS and Behavior, 2021, 25, 3115-3127.	1.4	6
330	Hepatitis C virus infection in United States correctional institutions. Current Hepatitis Reports, 2004, 3, 112-118.	0.3	5
331	Criminal justice measures for economic data harmonization in substance use disorder research. Health and Justice, 2018, 6, 17.	0.9	5
332	Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials, 2019, 82, 77-84.	0.8	5
333	Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs. Journal of Substance Abuse Treatment, 2020, 111, 16-22.	1.5	5
334	Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLoS ONE, 2020, 15, e0228433.	1.1	5
335	Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. Military Medical Research, 2021, 8, 32.	1.9	5
336	Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal of Drug Policy, 2022, 101, 103558.	1.6	5
337	A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova. International Journal of Drug Policy, 2022, 104, 103683.	1.6	5
338	Active syphilis and its association with HIV and sexual risk behaviours in a multicity sample of men who have sex with men and transgender women in Peru. Sexual Health, 2017, 14, 304.	0.4	4
339	Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 464-468.	0.6	4
340	The effects of opioid-agonist treatments on HIV risk and social stability: A mixed methods study of women with opioid use disorder in Ukraine. Journal of Substance Abuse Treatment, 2017, 83, 36-44.	1.5	4
341	The Impact of Housing and HIV Treatment on Health-Related Quality of Life Among People With HIV Experiencing Homelessness or Unstable Housing. American Journal of Public Health, 2018, 108, S531-S538.	1.5	4
342	Prisoner health status at three rural Haitian prisons. International Journal of Prisoner Health, 2018, 14, 197-209.	0.5	4

#	Article	IF	CITATIONS
343	Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Global Public Health, 2022, 17, 555-568.	1.0	4
344	Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study. Journal of Medical Internet Research, 2021, 23, e25428.	2.1	4
345	Multi-level implementation factors that influence scale-up of methadone maintenance treatment in Moldovan prisons: A qualitative study. Journal of Substance Abuse Treatment, 2022, 136, 108660.	1.5	4
346	Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis. Clinical Infectious Diseases, 2003, 36, e162-e164.	2.9	3
347	PRESERVING HUMAN RIGHTS IN THE ERA OF "TEST AND TREAT―FOR HIV PREVENTION. American Journal of Public Health, 2011, 101, 198-199.	1.5	3
348	Validation of the â€~drinking expectancy questionnaire for men who have sex with men' in <scp>P</scp> eru. Drug and Alcohol Review, 2015, 34, 559-566.	1.1	3
349	Attitudes toward medication-assisted treatment among fishermen in Kuantan, Malaysia, who inject drugs. Journal of Ethnicity in Substance Abuse, 2017, 16, 363-379.	0.6	3
350	Housing Experiences among Opioid-Dependent, Criminal Justice-Involved Individuals in Washington, D.C Journal of Urban Health, 2018, 95, 61-70.	1.8	3
351	Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal of Substance Abuse Treatment, 2019, 104, 34-41.	1.5	3
352	Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Journal of Substance Abuse Treatment, 2021, , 108619.	1.5	3
353	An expanding HIV epidemic among older adults in Ukraine: Implications for patient-centered care. PLoS ONE, 2021, 16, e0256627.	1.1	3
354	Pharmacological Treatment of Substance Abuse in Correctional Facilities: Prospects and Barriers to Expanding Access to Evidence-Based Therapy. , 2007, , 385-411.		3
355	mHealth Intervention to Improve Treatment Outcomes Among People With HIV Who Use Cocaine: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e28332.	0.5	3
356	Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug users. AIDS & Public Policy Journal, 2005, 20, 74-91.	0.2	3
357	Addiction Treatment as Prison Governance: A Critical Discourse Analysis of Methadone Delivery in Kyrgyz Prisons. Contemporary Drug Problems, 2022, 49, 106-120.	0.7	3
358	Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals of Medicine, 2022, 54, 1714-1724.	1,5	3
359	Epidemiology of HIV Infection and AIDS. Disease Management and Health Outcomes, 1997, 1, 304-322.	0.3	2
360	Letter to the Editor: regarding "Individual and Neighborhood Correlates of Membership in Drug-Using Networks With a Higher Prevalence of HIV in New York City (2006–2009)― Annals of Epidemiology, 2013, 23, 664-665.	0.9	2

#	Article	IF	CITATIONS
361	Alcohol use disorders and antiretroviral therapy among prisoners in Argentina. International Journal of Prisoner Health, 2013, 9, 40-50.	0.5	2
362	An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1297-1301.	0.6	2
363	A Self-report Measure to Detect Neurocognitive Impairment Among Incarcerated People Living with HIV in Malaysian Context: an Exploratory Factor Analysis. International Journal of Mental Health and Addiction, 2017, 15, 812-825.	4.4	2
364	Evaluation of HIV risk and outcomes in a nationally representative sample of incarcerated women in Azerbaijan, Kyrgyzstan, and Ukraine. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 793-797.	0.6	2
365	Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. AIDS and Behavior, 2021, 25, 3743-3753.	1.4	2
366	HIV/AIDS, hepatitis and tuberculosis-related mortality among incarcerated people: a global scoping review. International Journal of Prisoner Health, 2021, ahead-of-print, 66-82.	0.5	2
367	Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. , 0, .		2
368	Management of HIV/AIDS in Correctional Settings. , 2005, , 449-487.		2
369	HIV care continuum among cisgender and transgender women sex workers in Greater Kuala Lumpur, Malaysia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-7.	0.6	2
370	Preferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study. Journal of Urban Health, 2022, 99, 277-292.	1.8	2
371	News events and their relationship with US vape sales: an interrupted time series analysis. BMC Public Health, 2022, 22, 479.	1.2	2
372	Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 462-471.	0.9	2
373	Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLoS ONE, 2022, 17, e0267903.	1.1	2
374	Prevalence and Correlates of Active Amphetamine-Type Stimulant Use Among Female Sex Workers in Malaysia. Frontiers in Psychiatry, 0, 13, .	1.3	2
375	Adherence to Antiretroviral Therapy in Correctional Settings. Journal of Correctional Health Care, 1998, 5, 179-200.	0.2	1
376	HIV disease among substance users. , 2012, , 537-549.		1
377	Dual motivational model of pre-exposure prophylaxis use intention: model testing among men who have sex men in Ukraine. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 261-266.	0.6	1
378	Cost-Consequences and Health Outcomes of Emtricitabine and Tenofovir Alafenamide (FTC/TAF): A Novel Two-Drug, Fixed-Dose Combination for Human Immunodeficiency Virus (HIV) Patients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0

#	Article	IF	CITATIONS
379	Development and Psychometric Evaluation of the PrEP Sexual Expectancies (PSEXS) Scale. AIDS and Behavior, 2021, 25, 1192-1198.	1.4	0
380	Outpatient opioid use disorder treatment for the ID physician. , 2021, , 161-187.		0
381	Correlates of newly diagnosed HIV infection among cisgender women sex workers and transgender women sex workers in Greater Kuala Lumpur, Malaysia. International Journal of STD and AIDS, 2021, 32, 609-619.	0.5	Ο
382	Response. Chest, 2021, 159, 2116-2117.	0.4	0
383	HIV Disease Among Substance Users: Treatment Issues. , 2008, , 513-526.		Ο
384	Guidelines for Persons With HIV. Annals of Internal Medicine, 2012, 157, 833.	2.0	0
385	HIV, substance use, and mental health care in prisons. Lancet Psychiatry,the, 2022, , .	3.7	ο